Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma ... prednisolone alone had a 74% treatment failure rate at 30 days, reducing ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma, making $1.3 billion in sales last year. It is also being developed for other indications including ...